FDA Withdraws Black-Box Warnings from Menopause Patches
Three menopause treatment patches have had their black-box warnings removed, prompting discussions about patient safety and accessibility.
The US Food and Drug Administration (FDA) has announced that three additional patches used for menopause treatment will no longer carry black-box warnings. These warnings previously alerted patients to potential risks of cardiovascular disease, breast cancer, and dementia.
Recent Developments
This decision comes shortly after six menopause treatments had their warnings lifted in February. The FDA did not summon an advisory committee for this latest ruling and provided minimal explanation regarding the scientific rationale during a press briefing.
As concerns about transparency loom large, Reshma Ramachandran, an assistant professor at the Yale School of Medicine, voiced her worries. She emphasized that the removal of these serious warnings could mislead patients, particularly those with a history of hormone-sensitive cancers.
Ongoing Supply Shortages
Despite the critical nature of this decision, FDA officials highlighted the urgent issue of shortages affecting menopause hormone treatments (MHT). Dorothy Fink, a deputy director at the National Institute of Child Health and Human Development, noted that production of estrogen patches has doubled over the last year, aiming to improve access for patients.
However, reported stock-outs continue to frustrate many patients. Sarah Ibrahim, deputy center director for regulatory programs at the FDA’s Center for Drug Evaluation and Research, acknowledged the issue, saying that the demand for estradiol patches surged significantly following the relaxation of warnings.
Assessing Risk vs. Benefit
The FDA has justified the removal of black-box warnings, stating that new evidence suggests a different risk-benefit profile for healthy women under 60 who are within 10 years of menopause onset. Ibrahim remarked that previous warnings may have over-emphasized risks.
Estradiol patches are considered to have a lower risk profile compared to synthetic oral medications, as they directly enter the bloodstream, bypassing the liver. However, research indicates that higher doses may elevate risks for users.
Concerns About Transparency and Scientific Backing
Experts have raised alarms over the FDA's decision-making process. During the Trump administration, claims about MHT benefits were made without sufficient scientific backing, which included assertions regarding extended longevity. While many women may benefit from these treatments, the lack of an advisory committee and research references raises questions about the decision-making approach.
In the past, the FDA has avoided conventional advisory meetings, labeling them as “bureaucratic” and “expensive.” Yet, the recent panel meeting in July 2025 featured doctors and influencers who were strong advocates for MHT, raising concerns regarding conflicts of interest.
Additionally, many public voices, including the lead investigator of the Women’s Health Initiative—crucial to the MHT recommendations—were not allowed to testify, despite their presence. In response to audience concerns, the FDA has opened a public comment period.
Future Possibilities
Looking ahead, the FDA is also considering making vaginal estrogen products available over the counter, a move that could provide easier access to treatments for women experiencing menopause symptoms.
